CHICAGO — Lepodisiran, a small interfering RNA agent, lowered lipoprotein(a) levels at 180 days, with a reduction of more ...

Amgen (AMGN) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.

Based on Wall Street analyst estimates for 2025 EPS, Amgen trades at 15 times its projected earnings, while Merck sits at a ...

The case had been filed last year by Amgen after the state Prescription Drug Affordability Board determined that its big-selling medication called Enbrel is unaffordable and began a process to ...

This story was originally published on PharmaVoice. To receive daily news and insights, subscribe to our free daily PharmaVoice newsletter. What do you get when you combine the efforts of one of ...

Amgen (AMGN) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of ...

Amgen (AMGN) closed at $311.55 in the latest trading session, marking a +1.5% move from the prior day. This move outpaced the S&P 500's daily gain of 0.55%. Elsewhere, the Dow gained 1.01%, while the ...

Biotechnology company, Amgen, has announced that it has entered into a definitive agreement to acquire deCODE Genetics, a global leader in human genetics, for US $415 million. The all-cash ...

Unlike Traditional Chatbots, GVA Learning 360 Absorbs the Wisdom of Human Agents, Not Just Documents—Cutting AI Onboarding Time and Bringing Uniformity to AI and Human Customer Experiences New York, ...

Amgen is planning to push its olpasiran candidate for reducing lipoprotein(a) into phase 3 as quickly as possible as it tries to catch up with rival programmes at Novartis. The US biotech has just ...